Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer
Completed · Phase 2
Conditions studied: Ovarian Cancer, Peritoneal Cavity Cancer
In brief
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with docetaxel works in treating patients with relapsed or refractory ovarian epithelial or peritoneal cancer.
Key facts
- Study ID
- NCT00227721
- Run by
- Robert Morris
- People needed
- 30
- Starts
- 2004-02-01
- Expected to finish
- 2017-02-01
- Last updated by the study team
- 2020-12-02
Who can join
Age: 18 and older, up to 120. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Oakwood Cancer Center at Oakwood Hospital and Medical Center — Dearborn, Michigan, United States
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center — Columbus, Ohio, United States
- Northern Virginia Pelvic Surgery Assoc — Annandale, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.